Drug Trial Radar · NCT03201796
Prulifloxacin in Chronic Bacterial Prostatitis (CBP)
Last checked: Nov 21, 2026Latest source record: May 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
168
Actual
Start
Feb 2, 2016
Primary completion
May 19, 2020
Study completion May 19, 2020
Sponsor
- Lead sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.AIndustry
- Sponsor type
- Industry
- Collaborators
- Hippocrates Research
- First posted
- Jun 28, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study is to assess the efficacy and safety of prulifloxacin in comparison to levofloxacin in the treatment of patients affected by CBP.
Conditions
- Chronic Bacterial Prostatitis
Interventions
Prulifloxacin 600 mgDrug
Oral administration of one tablet once daily for 28 days of prulifloxacin 600 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
Levofloxacin 500mgDrug
Oral administration of one tablet once daily for 28 days of levofloxacin 500 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Eradication of bacterial growthTime frame: 7 days after the EOT
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
Urology Clinic General Hospital of Athens "GENNIMATAS"
Athens, Greece
Urology Department General Hospital of Piraeus "TZANEIO"
Piraeus, Greece
U.O. di Urologia- Azienda Ospedaliera San Giuseppe Moscati
Avellino, Italy
U.O. Dipartimento della Donna, del bambino e delle malattie urologiche - Azienda ospedaliero- Universitaria e Policlinico di Bologna
Bologna, Italy
Urologia- Azienda Ospedaliero - Universitaria "Policlinico - Vittorio Emanuele"
Catania, Italy
Clinica Urologica- Azienda Ospedaliero Universitaria Mater Domini
Catanzaro, Italy
Azienda Ospedaliero-Universitaria "Careggi"
Florence, Italy
Azienda Ospedaliera Universitaria "Federico II"- Dip. Di Ostreticia, ginecologia, Urologia
Naples, Italy
Clinica Urologica del Dipartimento di Scienze Chirurgiche- Policlinico Universitario Agostino Gemelli di Roma
Roma, Italy
S.C. Urologia- AO "Città della Salute e della Scienza" di Torino - OSP.S. GIOV.BATTISTA MOLINETTE
Torino, Italy
Urologia- Ospedale di Trento- Presidio ospedaliero S. Chiara - Azienda Provinciale per i servizi sanitari (APSS)
Trento, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.